Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort. J Pediatr Gastroenterol Nutr 2015 Oct;61(4):408-10
Date
04/18/2015Pubmed ID
25885878DOI
10.1097/MPG.0000000000000817Scopus ID
2-s2.0-84942509029 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
The aims of the study were to describe infliximab adherence in a pediatric inflammatory bowel disease cohort, to identify demographic and disease factors associated with adherence, and to examine differences in acute care use among adherent and nonadherent patients. Charts of patients who received infliximab at the Children's Hospital of Wisconsin (CHW) between October 2010 and October 2012 were retrospectively reviewed. A total of 151 patients met the inclusion criteria; 91.4% of the patients were adherent. Nonadherent patients had more emergency room visits and hospitalizations than adherent patients. The study is the first to show high adherence rates to infliximab in a pediatric cohort.
Author List
Vitale DS, Greenley RN, Lerner DG, Mavis AM, Werlin SLAuthor
Diana Lerner MD Associate Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAnti-Inflammatory Agents, Non-Steroidal
Child
Child, Preschool
Cohort Studies
Colitis, Ulcerative
Crohn Disease
Emergency Service, Hospital
Female
Gastrointestinal Agents
Hospitalization
Hospitals, Pediatric
Humans
Infliximab
Infusions, Intravenous
Maintenance Chemotherapy
Male
Medical Records
Medication Adherence
Retrospective Studies
Symptom Flare Up
Wisconsin
